Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636596 | 0.82 | PKM (0.53) | PKMCYP3A4CYP2C19L3MBTL1TSHR | |
| SCHEMBL2060101 | 0.78 | PKM (0.56) | PKMCYP3A4CYP2C19L3MBTL1TSHR | |
| SCHEMBL66579 | 0.76 | MAPT (0.49) | PKMCYP3A4CYP2C19L3MBTL1TSHR | |
| SCHEMBL13007128 | 0.75 | MEN1 (0.60) | PKMCYP3A4CYP2C19L3MBTL1TSHR | |
| SCHEMBL14153169 | 0.75 | PKM (0.56) | PKMCYP3A4CYP2C19L3MBTL1TSHR | |
| SCHEMBL18018492 | 0.72 | PKM (0.53) | PKMCYP3A4CYP2C19L3MBTL1TSHR | |
| SCHEMBL7904534 | 0.72 | PKM (0.45) | PKMCYP3A4CYP2C19L3MBTL1TSHR | |
| SCHEMBL1711115 | 0.72 | PKM (0.85) | PKML3MBTL1TSHRMAPTMEN1 | |
| SCHEMBL24193774 | 0.71 | MAPT (0.74) | PKMCYP3A4CYP2C19L3MBTL1MAPT | |
| SCHEMBL18423004 | 0.70 | MAPT (0.56) | PKMCYP3A4CYP2C19L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | PKM 1070/4885CYP3A4 215/4885CYP2C19 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.